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Abstract 
Campylobacter infections are among the most prevalent foodborne infections in humans, resulting in a massive 
disease burden worldwide. Broilers have been identified as the major source of campylobacteriosis and reduc‑
ing Campylobacter loads in the broiler caeca has been proposed as an effective measure to decrease the number 
of infections in humans. Failure of current methods to control Campylobacter in broilers stresses the urgency to 
develop novel mitigation measures. We obtained six nanobodies with a broad specificity, that recognize strains 
belonging to the two most relevant species, Campylobacter jejuni and Campylobacter coli. The target of the nano‑
bodies was identified as the major outer membrane protein, a porin that contributes to bacterial virulence and 
viability. Multimerization of the nanobodies led to agglutination of C. jejuni cells, which may affect colonization in 
the chicken gut. These Campylobacter‑specific nanobodies may be useful to develop a strategy for preserving chick‑
ens from Campylobacter colonization.
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Worldwide, Campylobacter is one of the most com-
mon causes of gastroenteritis [1, 2]. Less than 500 bac-
teria are required to establish infection, hence small 
amounts present in food or water can cause human 
infections [3]. The Campylobacter species mostly associ-
ated with infection, in both industrialized and develop-
ing countries, are C. jejuni and C. coli [4]. Typical clinical 
symptoms of Campylobacter infections in humans are 
abdominal cramps, diarrhoea and fever. Usually, Campy-
lobacter enteritis is a self-limiting disease and antibi-
otic treatment is only necessary in persistent cases [5, 
6]. However, infections with C. jejuni can lead to severe 
complications like the Guillain–Barré syndrome, a 
paralyzing neuropathological disease [7, 8]. The favoured 
environmental reservoir of C.  jejuni is the intestinal 
tract of poultry, that is considered the natural host of C. 
jejuni. The elevated body temperature of chickens (i.e. 
42  °C) corresponds to the optimal growth temperature 
of C. jejuni, which makes them an outstanding reservoir 
for the bacteria [9]. Campylobacter mainly colonizes the 
mucus layer of the intestinal tract and is abundantly pre-
sent in the caecum. Up to  109 CFU/g faecal content can 
be reached [10, 11]. At slaughter age, up to 80% of the 
flocks worldwide are contaminated with Campylobacter 
bacteria. Consumption and handling of contaminated 
poultry meat or carcasses are the most common causes 
of Campylobacter infections in humans [12–15].
Since poultry plays such an important role in transmis-
sion, a decrease of the colonization of poultry by Campy-
lobacter will lead to a reduction of Campylobacter-related 
enteritis cases in humans [16]. Hygiene and biosafety 
play an essential role in the control of Campylobacter 
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infections in poultry, but these methods alone are not suf-
ficiently effective and must be complemented with novel 
control approaches [17]. Still, no effective control meas-
ures are available to prevent or reduce the prevalence of 
C. jejuni in poultry during primary production [18, 19]. 
The addition of antibiotics to animal feed is not accept-
able, as this leads to an increasing number of resistant 
strains which has serious consequences for the treatment 
of humans [20, 21]. Therefore, a wide range of alternative 
approaches have been screened. An effective vaccine has 
not yet been developed and the use of fatty acids, bio-
active plant additives or probiotics did not lead to the 
desired in vivo effect [22–24]. Other alternatives, like the 
use of bacteriophages and bacteriocins, are more promis-
ing, however, more research is required [24–26]. Mater-
nal anti-Campylobacter antibodies protect young chicks 
during the first 2–3 weeks [27, 28]. Consequently, the use 
of maternal antibodies, isolated from eggs of immunized 
hens, has been assessed for the passive immunization of 
infected chickens. The results were promising for the use 
as therapeutic treatment [29, 30].
In this study, we describe the isolation and characteri-
zation of nanobodies (Nb) recognizing multiple Campy-
lobacter strains. Nanobodies are the antigen-binding 
domains of heavy chain antibodies found in Camelidae 
[31]. They possess a number of advantages over antibod-
ies, which makes their use attractive for diagnostic and 
therapeutic purposes. Nanobodies interact with their 
antigen with high affinity and specificity, they are highly 
stable and soluble and can be expressed in microbial 
expression systems [32, 33]. The nanobodies isolated 
in this study bind with the major outer membrane pro-
tein (MOMP). Outer membrane proteins (OMP) play a 
major role in adhesion and invasion during Campylobac-
ter infections [34]. Therefore nanobodies targeting these 
proteins could be interesting tools for the development of 
a control strategy. One of the outer membrane proteins 
important for virulence of Campylobacter is the MOMP, 
encoded by the porA-gene. MOMP is a conserved trim-
eric β-barrel porin involved in adhesion [35]. The porin 
is also essential for viability of Campylobacter, as its dele-
tion results in a lethal phenotype [36, 37]. It is required 
for structural organization and stabilization of the outer 
membrane and it makes the diffusion possible of com-
pounds, like nutrients and antibiotics, across the mem-
brane [38, 39].
Materials and methods
Bacterial strains and growth condition
The bacterial strains that were used in this study are 
indicated in Table 1. C. jejuni KC40 was used as a refer-
ence strain. C. jejuni was grown on Nutrient Broth Nr.2, 
solidified with 1.5% agar (NB2, CM0067; Thermo Fisher 
Scientific) under microaerobic conditions (Oxoid™ 
CampyGen™, Thermo Fisher Scientific) at 42 °C for 48 h. 
Escherichia coli strains were cultured on LB medium 
(Duchefa Biochemie), supplemented with the appropri-
ate antibiotics if necessary.
Table 1 Bacterial strains used in this study
* The fla-DGGE analysis is described in Najdenski et al. [51].
+ The MLST results are described in Hermans et al. [30].
a Isolates obtained from a poultry farm or a slaughterhouse, provided by Dr. 
Marc Heyndrickx (Institute for Agricultural and Fisheries Research, Technology 
and Food Science Unit—Food Safety, Melle, Belgium).
b Clinical isolates obtained from faeces of infected patients, provided by Dr. D. 
Martiny (Microbiology Department, Iris-lab, Brussels, Belgium). MLST analysis 
showed that the isolates belong to different clonal complexes (CC-21, CC-464, 
CC-21, CC-206, CC-48, CC-45) (D. Martiny, personal communication).
c Isolates obtained from chickens, provided by Dr. Marc Heyndrickx (Institute for 
Agricultural and Fisheries Research, Technology and Food Science Unit—Food 
Safety, Melle, Belgium).
Species Strain Source
C. jejuni KC40 Environment  chickena*+
7P‑6.12 Chickena+
10C‑6.1 Chickena+
10KF‑1.16 Chickena+
10KF‑4.12 Chickena+
10VTDD‑8 Chickena+
KC59.1 Chickena*
KC64.1 Chickena*
KC67.1 Chickena*
KC84.1 Chickena*
KC96.1 Chickena*
KC101 Environment  chickena*
Cam12/0214 Humanb
Cam12/0231 Humanb
Cam12/0146 Humanb
Cam12/0152 Humanb
Cam12/0173 Humanb
Cam12/0197 Humanb
Cam12/0156 Humanb
Cam12/0190 Humanb
Cam12/0202 Humanb
Cam12/0222 Humanb
Cam12/0183 Humanb
C. coli 52/P Chickenc
70/P Chickenc
K43/5 Chickenc
KC7 Chickenc
MB3361 Chickenc
E. coli TG1 [68]
DH5α [69]
WK6 [70]
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Phage library construction and selection 
of anti‑Campylobacter nanobodies
A detailed protocol for immunization, generation of a 
nanobody library and selection by phage panning has 
been described [40]. C. jejuni KC40 cells were heat-inac-
tivated at 55 °C for 1 h. An alpaca was injected six times 
with 1.6 × 108 inactivated C. jejuni KC40. Peripheral lym-
phocytes were isolated from the blood of the immunized 
alpaca, from which RNA was isolated and converted to 
cDNA [40]. PCR on the cDNA was used to amplify the 
sequences encoding the variable domains of heavy chain 
antibodies. The resulting PCR fragments were cloned in 
the phage display vector pHen4 [41] and transformed in 
E. coli TG1 cells. Phage display was used for the selection 
of Campylobacter-specific nanobodies from the immune 
library. The phage library was panned twice against an 
outer membrane extract. Binding phages from the sec-
ond panning were eluted and used for infection of E. coli 
TG1. From 95 individual E. coli TG1 transformants, a 
periplasmic extract was prepared and used in an ELISA, 
to confirm their specificity for the outer membrane 
extract of Campylobacter. Subsequently, the nanobody-
encoding genes from 21 positive clones were amplified 
from the pHen4 plasmid for sequencing.
Tagging of the nanobodies
The nanobodies were cloned in the pHen6C vector [42], 
designed for the introduction of a histidine-tag (His-tag) 
at the C-terminus. PCR was performed using In-Fusion 
primers IF-NB1 (5′-TGGCCCAGGTGCAGCTGCAG-
GAGTCTGGAG-3′) and IF-NB2 (5′-TGAGGAGACG-
GTGACCTGGGTCC-3′). For the introduction of the 
PCR fragments in the pHen6C, the vector was digested 
with PstI and BstEII and the cloning was carried out with 
the In-Fusion® HD Cloning Kit (Takara Bio USA, Inc).
For the construction of the strep-tagged nanobod-
ies, the pHen6C derivatives encoding the His-tagged 
nanobodies were used. The His-tag was removed using 
the BstEII and EcoRI restriction enzymes. The strep-
tag was introduced by ligation of annealed oligo’s 
(5′-GTCACCGTCTCCTCATGGAGCCACCCGCAGTT 
CGAAAAATAAGTTTAAACTAC-3′ and 5′-AATTTAG 
TTTAAACTTATTTTTCGAACTGCGGGTGGCTCCA 
TGAGGAGAC G-3′) in the linearized pHen6C vectors.
The resulting constructs were transformed into 
 CaCl2-competent E. coli DH5α [43] and transformants 
were selected on LB-agar plates supplemented with 
100  µg/mL carbenicillin. Colonies were screened by 
PCR with the primers FP24 (5′-CGCCAGGGTTTTC-
CCAGTCACGAC-3′) and RP24 (5′–AGCGGA-
TAACAATTTCACACAGGA-3′). PCR-positive colonies 
were sequenced to confirm that the constructs were 
correct.
Expression and purification of anti‑Campylobacter 
nanobodies
Clones encoding C-terminally His-tagged anti-Campy-
lobacter nanobodies were introduced in E. coli WK6 
for expression and purification. The bacterial cells were 
grown at 37  °C in LB medium supplemented with car-
benicillin (100  µg/mL). When  OD660  nm 0.6–0.8 was 
reached, nanobody expression was induced at 30  °C by 
adding 1  mM isopropyl β-d-1 thiogalactopyranoside 
(Thermo Fisher Scientific). After overnight incubation, 
the periplasmic content was extracted and the nanobod-
ies were purified.
His-tagged nanobodies were purified by nickel-affinity 
chromatography using HisTrap HP columns (GE Health-
care Life Sciences). The columns were equilibrated and 
washed with 20 mM Tris–HCl, 1 M NaCl, pH 8.0. Nan-
obodies were eluted using a linear gradient to 1 M imi-
dazole. The eluted protein fractions were analysed by 
SDS-PAGE, using 12.5% acrylamide gels stained with 
Coomassie blue dye. The PageRuler™ Prestained Protein 
Ladder (Thermo Fisher Scientific) is used as a molecu-
lar weight marker. Fractions containing pure nanobod-
ies were pooled and dialyzed against phosphate-buffered 
saline (PBS).
Strep-tagged nanobodies were purified using Strep-
Trap HP columns (GE Healthcare Life Sciences). These 
were equilibrated and washed with 100  mM Tris–HCl, 
150  mM NaCl, 1  mM EDTA, pH 8.0 and nanobodies 
were eluted with a linear gradient to 2.5 mM desthiobio-
tin. Fractions containing pure nanobodies were dialyzed 
against PBS.
Whole‑bacterial cell ELISA
The interaction of the purified nanobodies, with differ-
ent C. jejuni and C. coli isolates was assessed by means 
of a whole-cell ELISA. The bacteria were grown on NB2-
agar plates and after 48 h the cells were harvested from 
the plates with PBS. The bacterial cells were centrifuged 
at 3600 g for 15 min and washed in PBS. Bacterial cells 
were fixed with 2.5% (v/v, final concentration) of meth-
anol-stabilized 37% formaldehyde solution (Merck), fol-
lowed by incubation for 100  min at 42  °C. Afterwards, 
the fixed bacterial cells were pelleted by centrifugation. 
The pellet was resuspended in coating buffer (150  mM 
 Na2CO3, 46 mM  NaHCO3) and the  OD660 was adjusted 
to 0.3. From the suspension, 100 µL per well was used to 
coat a 96-well plate. After overnight incubation at 4  °C, 
the plates were washed five times with PBS +  0.05% 
 Tween®-20. To reduce nonspecific interactions, 200  µL 
5% (w/v) bovine serum albumin (BSA) was used per 
well and incubated for 2 h. Subsequently, the wells were 
washed five times and 100 µL/well of the anti-Campylo-
bacter nanobodies (50  µg/mL) was added, followed by 
Page 4 of 14Vanmarsenille et al. Vet Res  (2017) 48:86 
1 h incubation at room temperature. Afterwards, mouse 
anti-Histidine tag monoclonal antibody (1:1000) (AbD 
Serotec) and goat anti-mouse IgG conjugated to alkaline 
phosphatase (AP) (1:5000) (Sigma-Aldrich) were added 
consecutively. The ELISA was developed by addition of 
2 mg/mL para-nitrophenyl phosphate (p-NPP) in ELISA 
buffer (100 mM Tris–HCl, pH 9.5, 5 mM  MgCl2, 100 mM 
NaCl). The OD was read at 405 nm.
Preparation of outer membrane extract
Campylobacter jejuni KC40 was cultured on NB2-agar 
plates and the bacterial cells were resuspended in 10 mM 
HEPES pH 7.4. The cells were lysed by passing the culture 
twice through the Cell Cracker (Glen Creston, Stanmore, 
VK, UK) at 1000  psi (pound-force per square inch) at 
4 °C. To remove cell debris, the disrupted cell suspension 
was centrifuged at 12 000 g at 4  °C for 10 min. The fur-
ther isolation of the outer membranes in the supernatant 
was performed as described [44], with the exception that, 
after the sarkosyl treatment, the membranes were centri-
fuged for 30 min instead of 1 h. The obtained OMPs were 
stored in 20 mM HEPES pH 7.4 at −20 °C.
Purification of the MOMP
The MOMP was purified from a total membrane extract. 
The outer membrane proteins were incubated in the 
presence of 0.3% n–octylpolyoxyethylene (octyl-POE) 
for 20 min at 4  °C. The insoluble proteins were pelleted 
by centrifugation at 100  000  g for 1  h. This step was 
repeated once, followed by two successive extraction 
steps with 0.5% octyl-POE. The obtained fractions were 
further purified using anion-exchange chromatography. 
A Resource Q column (GE Healthcare Life Sciences) was 
equilibrated with 20  mM sodium phosphate buffer pH 
6.0 supplemented with 0.6% octyl-POE and the extracted 
proteins were loaded on the equilibrated column. Elution 
was achieved using a linear gradient to 1  M NaCl. The 
eluted fractions were analysed by SDS-PAGE, stained 
with Coomassie blue dye. Pure fractions were pooled and 
dialysed against 20 mM sodium phosphate buffer pH 7.6 
supplemented with 0.6% octyl-POE.
Interaction of nanobodies and outer membrane proteins 
in ELISA
The interaction of the nanobodies with the outer mem-
brane extract and the purified MOMP was investigated 
using ELISA. Native or denatured outer membrane 
extract and purified MOMP were coated in a 96-well 
plate at a concentration of 1 µg/mL. The ELISA was fur-
ther carried out as described above. For the ELISA with 
outer membrane extract, tenfold serial dilutions were 
made of the anti-Campylobacter nanobodies, starting 
from 50 µg/mL.
Pull‑down assay for antigen determination
To isolate OMP-Nb complexes, the  Dynabeads® His-Tag 
Isolation and Pulldown kit (Thermo Fisher Scientific) 
was used. Twenty microliter of nanobodies (1.0 mg/mL) 
was added to 500  µL of the isolated outer membrane 
proteins (1.2 mg/mL) and the mixture was incubated for 
2 h at 4 °C on a roller. The His-tagged nanobodies inter-
act with the  Co2+-coated magnetic beads. The procedure 
was followed as described in the manual, with the excep-
tion that the samples containing the OMP-Nb complexes 
where incubated overnight with the Dynabeads at 4  °C. 
An SDS-PAGE was performed on the eluted complexes 
and the gel was stained with the SilverQuest™ Silver 
Staining Kit (Thermo Fisher Scientific). The relevant 
protein bands were excised from the gel, destained and 
digested with trypsin for further analysis by liquid chro-
matography–tandem mass spectrometry (LC–MS/MS) 
as described [45].
Western blotting was performed on denatured and 
non-denatured proteins. The non-denatured samples, 
were run on a 12.5% acrylamide gel in running buffer 
composed of 14.4 g glycine, 3.03 g Tris and 0.250 g SDS 
per litre. After electrophoresis, the proteins were either 
transferred to a polyvinylidene difluoride (PVDF) mem-
brane, activated with methanol, or stained with Coomas-
sie blue dye. After transfer, the membrane was washed 
five times with PBS +  0.2% Triton X-100, followed by 
an incubation of 1  h at 4  °C with blocking buffer (PBS 
+ 10% milk powder). The washing step was repeated in 
between every incubation step. The washed PVDF mem-
brane was then incubated with 5  µg/mL anti-Campy-
lobacter nanobody, diluted in PBS +  0.2% Triton X-100 
+ 5% milk powder for 1  h at 4  °C. For the detection of 
the His-tagged nanobodies, a mouse anti-Histidine tag 
monoclonal antibody (1:1000) (AbD Serotec) was added 
and incubated for 1 h at 4 °C. The western blot was devel-
oped with a goat anti-mouse IgG conjugated to alkaline 
phosphatase (AP) (1:5000) (Sigma-Aldrich). After 1 h at 
4  °C, substrate (50 µL NBT/BCIP in 100 mM Tris–HCl, 
pH 9.5, 5 mM  MgCl2, 100 mM NaCl) was added to the 
membrane and incubated at 37 °C.
Microscale thermophoresis (MST)
MST, an immobilization-free method, was used for the 
characterization of the Nb-MOMP interaction. This 
technique allows the study of interactions of biomol-
ecules in solution. A NanoTemper Monolith NT.115 
instrument (NanoTemper Technologies) was used for the 
binding experiments, wherein a temperature gradient is 
formed in glass capillaries by means of an infrared laser. 
The movement of the biomolecules along this gradient 
is affected by changes in size or charge and modifica-
tions in their hydration shell. For the saturation binding 
Page 5 of 14Vanmarsenille et al. Vet Res  (2017) 48:86 
experiment, an anti-Campylobacter nanobody was fluo-
rescently labelled via free amino-groups with Dylight 650 
NHS Ester (Thermo Fisher Scientific). The labelled nano-
body (constant concentration of 32 nM) was mixed with 
twofold serial dilutions of MOMP, ranging from 0.3 nM 
to 5.0  µM. The interaction of the proteins was meas-
ured in 20  mM sodium phosphate buffer pH 7.6 sup-
plemented with 150 mM NaCl and 0.6% octyl-POE. The 
samples were loaded into the glass capillaries (Monolith™ 
NT.Automated Standard Treated Capillary Chips), the 
thermophoresis measurements were performed (MST 
power 10% and LED 100%) and the data were analysed 
using the NT Analysis software (NanoTemper Technolo-
gies). Data were normalized to ΔFnorm [‰] [46]. A com-
petition experiment was used to determine whether an 
unlabelled nanobody can impede the interaction of the 
labelled nanobody and the MOMP. In this experiment, 
the unlabelled nanobody was used at a constant concen-
tration of 10 µM and mixed with a twofold serial dilution 
of MOMP (0.3 nM to 5.0 µM). Afterwards, the labelled 
nanobody was added to the suspension at a constant con-
centration of 32 nM. The experiment was further carried 
out as described above.
Saturation and competition binding assay
A saturation binding assay was performed using ELISA, 
to determine the interaction between a constant concen-
tration MOMP (1 µg/mL) and tenfold serial dilutions of 
His-tagged Nb84, ranging from 5 × 10−7 to 5 × 101 µg/
mL. In a second experiment, the influence of competi-
tors on this interaction was examined. Therefore MOMP 
(1 µg/mL) was coated in a 96-well plate, after which serial 
dilutions (from 5  ×  10−7 to 5  ×  101  µg/mL) of strep-
tagged anti-Campylobacter nanobodies, used as competi-
tors, and a constant concentration of His-tagged Nb84 
(5  ×  10−2  µg/mL) were simultaneously added. Bound 
His-tagged nanobody was detected with a mouse anti-
Histidine tag monoclonal antibody and goat anti-mouse 
IgG conjugated to alkaline phosphatase (AP).
Sequence analysis of porA‑gene of C. jejuni and C. coli 
isolates
To analyse the genetic variability of MOMP between 
different Campylobacter strains, the porA-gene was 
amplified with primers F3 (5′-ATGAAACTAGTTA 
AACTTAGTTTA-3′) and R3 (5′-GAATTTGTAAAGA 
GCTTGAAG-3′) [47]. A single colony of every isolate 
was resuspended in 50  µL deionized  H2O and the sus-
pension was frozen at −80 °C and subsequently boiled at 
95  °C for 5  min. Of the suspension 1  µL was used as a 
template.
Immunofluorescence microscopy
Campylobacter jejuni KC40 cells were fixed during 
10 min with a final concentration (v/v) of 1.2% formalde-
hyde (methanol-stabilized, Merck). Fixed cells were spot-
ted on 0.1% poly-l-lysine treated glass slides and dried. 
The microscope slides were treated with 5% BSA for 
15 min, followed by the addition of 30 µL anti-Campylo-
bacter nanobodies (50 µg/mL) and incubation for 1 h at 
room temperature. The bound nanobodies were detected 
in two consecutive steps. First, mouse anti-His mono-
clonal antibodies (1:200) (AbD Serotec) were added and 
incubated for 1 h at room temperature. Anti-mouse IgG 
conjugated to Alexa Fluor 488 (1:250) (Thermo Fisher 
Scientific) was then added for fluorescent labelling. After 
1 h, the slides were washed with PBS and dried. As a 
negative control, anti-F4 nanobodies [48, 49] were used. 
In between every step, the glass plates were washed with 
PBS and dried.
Multimerization of nanobodies
Selected nanobodies were coupled to  Co2+-coated mag-
netic Dynabeads  (Dynabeads® His-Tag Isolation and 
Pulldown, Thermo Fisher Scientific) to make them mul-
tivalent, using the buffers described in the manual. Nano-
bodies (24  µg) were added to 300  µg of Dynabeads and 
the mixture was incubated at room temperature during 
10  min on a roller. Hereafter, the beads were washed 
three times to remove the unbound nanobodies and the 
nanobody-coupled beads were stored in pull-down buffer 
at 4 °C.
Campylobacter jejuni KC40 cells were harvested from 
NB2-agar plates with NB2 medium and a suspension 
with  OD660 2.0 was used for the agglutination assay. The 
bacterial cells and nanobody-coupled beads were mixed 
in a 1:4 ratio in a final volume of 10  µL on a slide. The 
slides were incubated at room temperature and examined 
visually and by phase contrast microscopy for agglutina-
tion. As a negative control, the agglutination of Campy-
lobacter bacteria in the presence of beads coupled with 
anti-F4 nanobodies was assessed [48, 49].
Results
Isolation of anti‑Campylobacter nanobodies with a broad 
specificity
To generate an immune library, an alpaca was immu-
nized with heat-inactivated KC40 bacteria. From this 
library, 21 Campylobacter-specific nanobodies were 
obtained after two consecutive panning rounds against 
an outer membrane fraction of the C. jejuni strain 
KC40. These nanobodies belong to 12 different fami-
lies (Figure  1) showing less than 80% identity in their 
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complementarity-determining region 3 (CDR3), as 
defined by Pardon et al. [40]. A significant level of diver-
sity is found among Campylobacter strains isolated from 
poultry [50]. For this reason, we selected one nanobody 
from each family and examined whether these display 
a broad detection range by testing their binding with 
Campylobacter strains [30, 51], belonging to different 
subtypes (Table  1). Whole-cell ELISA analysis showed 
that the six anti-Campylobacter nanobodies have a broad 
specificity range (Additional file 1). They interacted with 
all 23 tested C. jejuni strains, both from chickens and 
human patients, and with the 5 tested C. coli isolates. 
These data suggest that these nanobodies recognize con-
served antigens on the cell surface of the Campylobacter 
strains.
Nanobodies interact with folded outer membrane proteins
Whole-cell ELISA showed that the six nanobodies with 
broad specificity recognize epitopes exposed on the bac-
terial cell surface. ELISA was used to determine whether 
the nanobodies recognize conformational or linear 
epitopes (Figure 2). The nanobodies showed strong bind-
ing with native outer membrane proteins, while the inter-
action was significantly reduced after denaturation of the 
outer membrane proteins. These results indicate that the 
nanobodies bind to conformational epitopes present on 
outer membrane proteins.
MOMP is the target of the isolated anti‑Campylobacter 
nanobodies
To determine the antigens recognized by the six nano-
bodies with broad specificity, a pull-down experiment 
Figure 1 Amino acid sequence alignment of anti-Campylobacter nanobodies selected for their broad specificity. The structural frame‑
work regions are indicated by FR1–FR4 and the red boxes specify the CDRs. On the basis of the variation of the amino acid sequence of the CDR3, 
the nanobodies were divided in twelve unique groups.
Figure 2 Anti-Campylobacter nanobodies interact with native outer membrane proteins. Serial tenfold dilutions of the nanobodies were 
used in ELISA to assess the binding with linear or conformational epitopes. OMPs (1 µg/mL) were coated in a 96‑well plate and the interaction of 
His‑tagged nanobodies with native, untreated OMP, and with denatured protein extract was measured. Binding of A Nb5, B Nb22, C Nb23, D Nb24, 
E Nb49 and F Nb84 was measured. For detection, mouse anti‑Histidine tag monoclonal antibody and goat anti‑mouse IgG conjugated to alkaline 
phosphatase were used. The error bars represent the standard deviations.
Page 7 of 14Vanmarsenille et al. Vet Res  (2017) 48:86 
with magnetic beads was performed. Complexes with an 
outer membrane protein were isolated with three of the 
six nanobodies (Nb5, Nb22 and Nb84). The bound pro-
teins were digested with trypsin and the peptides were 
analysed by LC–MS/MS. In each case, the amino acid 
sequences of the peptides corresponded to the MOMP 
sequence of C. jejuni NCTC 11168 (UniProtKB - P80672) 
(Additional file 2), a porin that is a crucial virulence fac-
tor of Campylobacter. The MOMP was subsequently 
purified from C. jejuni KC40 bacteria and binding with 
the three nanobodies was confirmed by western blotting. 
The binding of Nb84 with native MOMP is shown in Fig-
ure  3A. The western blot clearly shows a protein band 
corresponding to native MOMP. The western blot with 
the nanobodies shows no interaction with the denatured 
MOMP (Figure  3B). This confirms the interaction with 
surface-exposed epitopes of MOMP. Similar results were 
obtained for the five other nanobodies with broad speci-
ficity. ELISA further showed that the other nanobodies 
with less broad specificity also recognize native MOMP 
(Additional file 3).
Affinity determination and competitive binding assay
We determined the strength of the interaction between 
MOMP and the nanobodies Nb5, Nb22 and Nb84 using 
microscale thermophoresis (MST). Therefore, the nano-
bodies were fluorescently labelled and incubated with 
increasing concentrations of MOMP (Figure  4; Addi-
tional file  4). Changes in the thermophoretic properties 
upon complex formation were plotted, to obtain infor-
mation on the dissociation constant  (KD-value). Nb22 
and Nb84 bind MOMP with intermediate nanomolar 
affinities  (KD = 118 ± 48 nM and  KD = 422 ± 159 nM, 
respectively). For Nb5, it was not possible to determine 
the dissociation constant because of a high signal to noise 
ratio.
The specificity of the binding curves was confirmed by 
adding an excess of the same unlabelled nanobody, which 
resulted in a loss of the MST signal (Figure 4C). In addi-
tion, a competitive MST assay was performed by adding 
an excess of a different unlabelled nanobody, that can 
potentially compete with the binding of the labelled nan-
obody to MOMP. When adding either unlabelled Nb5 or 
Nb22, no clear shift in the MST signal, corresponding to 
Figure 3 Confirmation of the binding of Nb84 with native MOMP. The purified MOMP monomer was subjected to non‑denaturing (A) and 
denaturing (B) SDS‑PAGE and transferred to a PVDF membrane for western blotting in which the membrane was first incubated with Nb84. Nb84 
shows clear interaction with folded but not with unfolded MOMP. His‑tagged Nb84 was added as a positive control. The interaction of the native 
protein with Nb84 was analysed using a mouse anti‑Histidine tag monoclonal antibody and goat anti‑mouse IgG conjugated to alkaline phos‑
phatase. The PageRuler™ prestained protein ladder was used as a molecular weight marker.
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the binding of labelled Nb84 to MOMP, was observed 
(Figures 4A and B). These data show that these nanobod-
ies do not bind the antigen simultaneously, suggesting 
that they may recognize the same, adjacent or overlap-
ping epitopes. However, we cannot exclude the possibility 
that these nanobodies may still bind to different epitopes 
and interfere with each other’s binding by inducing con-
formational changes.
To confirm the findings of the MST competition assay, 
we set up a competitive ELISA. The influence of strep-
tagged nanobodies, of the 12 different families, on the bind-
ing of His-tagged Nb84 to MOMP was assessed (Figure 5; 
Additional file 5). Dose-dependent inhibition of the bind-
ing was confirmed for nine of the twelve nanobodies. For 
the other three nanobodies (Nb32, Nb34 and Nb45), it was 
shown that they could bind to MOMP simultaneously with 
Nb84, which indicates they recognize different epitopes.
Variability in the porA‑gene encoding MOMP
The MOMP of C. jejuni and C. coli is characterised by 
high genetic diversity. Little variability is observed in the 
transmembrane domains, in contrast to high variabil-
ity in the extracellular loops [52]. The MOMP-encoding 
porA-gene of the 23 C. jejuni and the 5 C. coli stains was 
PCR-amplified and sequenced (Additional file  6). Based 
on the MOMP structure solved by Ferrara et  al. [39], 
the extracellular loops and β-strands were identified in 
the sequence. Since the broad specificity range nano-
bodies bind to the surface of Campylobacter cells, we 
can assume that they interact with one of the surface-
exposed loops of MOMP. These loops are however most 
variable amongst the sequenced MOMP genes. Sequence 
analysis shows that the extracellular loops L3 and L6 are 
the most conserved, in length and amino acid sequence, 
making these prime candidates to be recognized by the 
six nanobodies with a broad specificity range. Mapping of 
the sequences on the structure of MOMP confirms that 
the highest variability is located in the extracellular loops, 
while the sequence in the β-barrel structure is highly 
conserved (Additional file 7).
The sequence diversity in L3 and L6 in different C. 
jejuni and C. coli strains was analysed (Additional file 8). 
The MOMP encoding sequences in the MLSTdb data-
base [53] were used for the analysis of the L6 region. 
Since the sequence of L3 is not present in the MLSTdb 
database, sequences were obtained from the NCBI data-
base using Blastp with the porA sequence from C. jejuni 
KC40 as a query [54]. Comparison of the porA amino 
acid sequences, showed that the majority (81.9% or 1827 
out of 2230) of analysed Loop 6 sequences and 92.5% 
(620 out of 670) of analysed Loop 3 sequences all carry 
amino acid substitutions at positions found in the L6 and 
Figure 4 MST analysis of the binding of anti-Campylobacter Nb84 with the purified MOMP monomer. The binding curve of Nb84 with 
the MOMP monomer was obtained in a saturation binding experiment. The formation of Nb84‑MOMP complexes was measured at constant 
concentrations of the fluorescently labelled Nb84 (32 nM) and varying concentrations of unlabelled MOMP (0.3 nM–5 µM). Data were normal‑
ized to ΔFnorm [‰]. The competitive binding curves visualise the inhibition of binding of the fluorescently labelled Nb84 (32 nM) with MOMP 
(0.3 nM–5 µM) by unlabelled A Nb5, B Nb22 and C Nb84 (10 µM). The error bars represent the standard deviations.
Figure 5 Interaction between Nb84 and purified MOMP. 
To obtain the saturation binding curve, ELISA plates were coated 
with purified MOMP monomers (1 µg/mL) and the interaction 
with increasing concentrations of His‑tagged Nb84 (1 × 10−6 to 
1 × 102 µg/mL) was measured. A competition assay was performed 
to assess the inhibition of the interaction of His‑tagged Nb84 with 
MOMP by increasing amounts of strep‑tagged Nb84. His‑tagged 
Nb84 (5 × 10−2 µg/mL) and a serial dilution of strep‑tagged Nb84 
(1 × 10−6 to 1 × 102 µg/mL) were added to ELISA plates coated 
with MOMP (1 µg/mL). The ELISA was developed using a mouse 
anti‑Histidine tag monoclonal antibody and goat anti‑mouse IgG 
conjugated to alkaline phosphatase. The error bars represent the 
standard deviations.
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L3 loops of the 28 MOMPs analysed in this study. From 
our study, we know that these amino acid substitutions 
in the L3 and L6 loops of MOMPs do not impede nano-
body binding. The remaining 18.1% (403 of 2230) in case 
of L6 and 7.5% (50 of 670) encoding L3, contain amino 
acid changes on other positions. This does not imply that 
our six nanobodies with broad specificity would not bind 
these MOMP variants.
Interaction of anti‑Campylobacter nanobodies with the 
bacterial cell surface
Immunofluorescence microscopy was used to confirm 
the interaction of Nb22, Nb23 and Nb84 with the surface 
of C. jejuni KC40 cells (Figure 6). The results show clear 
fluorescence with the Campylobacter-specific nanobod-
ies, in comparison with an anti-E. coli nanobody that was 
used as a negative control.
To explore whether the anti-Campylobacter nanobod-
ies could agglutinate living C. jejuni KC40 cells, the six 
selected nanobodies were made multivalent, by cou-
pling them to magnetic Dynabeads via their histidine 
tag. Clear agglutination was observed when C. jejuni 
KC40 cells were added (Figure  7A). Here the results of 
Nb84 with C. jejuni KC40 are shown. Beads, coated with 
an anti-E. coli nanobody, were used as a negative con-
trol and caused no visible agglutination of Campylobac-
ter (Figure  7B). Additional negative controls were the 
Campylobacter bacteria and the beads coated with nano-
bodies alone (Figures 7C and D). The results confirm that 
the Campylobacter-specific nanobodies can bind with 
surface-exposed epitopes of C. jejuni KC40 and aggluti-
nate the latter.
Discussion
Substantial diversity of Campylobacter strains is found 
within broiler flocks and broilers are often colonized 
with multiple strains of C. jejuni [55]. Co-colonization 
by C. jejuni and C. coli has also been observed [13, 56]. 
Phage display technology was used to obtain a nanobody-
library against the C. jejuni strain KC40. Here we selected 
six anti-Campylobacter nanobodies that interact with the 
cell surface of 23 different C. jejuni isolates derived from 
a poultry farm, poultry carcasses or faeces of human 
patients, as well as with 5 C. coli isolates.
Next, MOMP was identified as the antigen recognized 
by twelve nanobodies, from which six show a broad spec-
ificity. Since MOMP is an abundant protein in the outer 
membrane and since it is highly immunogenic [57], these 
findings are not surprising. MOMP is an essential porin 
for Campylobacter bacteria, as deletion of the porA-gene 
is lethal, and it is a key virulence factor, crucial for colo-
nization [36, 37]. Islam et al. showed that the administra-
tion of recombinant MOMP, leads to protection of mice 
against colonization by heterologous C. jejuni strains 
[58]. Nanobodies targeting MOMP may interfere with 
its function and reduce colonization. Sequence analy-
sis of the porA-gene of the 28 isolates showed that the 
extracellular Loop 3 and Loop 6 are the most conserved. 
These loops are potential candidates to be recognized by 
the nanobodies. The sequence diversity in these loops in 
the publicly available porA-sequences, was analysed. The 
results indicate that 92.5% of the analysed Loop 3 and 
81.9% of the analysed Loop 6 sequences, carry amino 
acid substitutions at positions also found in the Loop 3 
and Loop 6 sequences of the 28 isolates used in this study 
and do not influence the nanobody binding.
The anti-Campylobacter nanobodies were shown to 
interact with conformational epitopes on MOMP. Com-
petition experiments showed that nine of the twelve 
anti-Campylobacter nanobodies could compete with 
each other’s binding to MOMP. This is an indication that 
they recognize the same or overlapping epitopes. Three 
of the anti-Campylobacter nanobodies were not able to 
inhibit the interaction of Nb84 with MOMP, hence they 
can simultaneously bind with MOMP. For Nb5, Nb22 
and Nb84, affinity measurements were performed. Nb22 
and Nb84 were shown to interact with MOMP with high-
nanomolar affinities. However affinity measurements 
with Nb5 gave no consistent results. The binding strength 
of the nanobodies can presumably be further increased 
by the generation of a bivalent construct. By using a flex-
ible peptide linker, dimers can be formed by coupling two 
nanobodies with the same specificity, resulting in higher 
avidity, or by combining two nanobodies binding differ-
ent epitopes, creating bi-specific constructs [59].
The monovalent character and the small size of nano-
bodies, lead to rapid clearance. Multimerization of nano-
bodies can increase the retention. The results show that 
multimerization of the anti-Campylobacter nanobodies 
by non-covalent coupling to magnetic beads, resulted 
in agglutination of C. jejuni cells. Nanobodies can be 
multimerized by surface-expression on Generally Rec-
ognized As Safe (GRAS) organisms [60]. Agglutination 
typically takes place at high bacterial densities [61]. In 
the gut agglutination of Campylobacter could promote its 
removal and reduce colonization [62, 63]. Alternatively, 
Moor et  al. showed that high-avidity IgA promotes the 
enchained growth of bacterial cells, leading to the for-
mation of clumps. The latter mainly takes place at lower 
cell densities and leads to an enhanced clearance of the 
bacteria [61]. Virdi et al. [49] fused nanobodies against F4 
fimbriae of enterotoxigenic E. coli (ETEC), with the Fc-
domain of porcine IgA. Arabidopsis thaliana seeds were 
used for the expression of these constructs and passive 
vaccination with the seeds resulted in the protection of 
weaned piglets against ETEC-infections. Chicken feed 
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Figure 6 Detection of the interaction of anti-Campylobacter nanobodies and C. jejuni KC40 by immunofluorescence microscopy. The 
interaction was detected by (A, C, E, G) immunofluorescence microscopy and the C. jejuni cells (B, D, F, H) were visualised by bright field micros‑
copy. A, B A nanobody specific for F4‑fimbriated enterotoxigenic E. coli shows no binding with the C. jejuni cells. C, D; E, F and G, H The anti‑Campy-
lobacter nanobodies Nb22, Nb23 and Nb84 respectively, binds specifically with the C. jejuni cells.
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supplemented with seeds containing anti-MOMP nano-
bodies, fused to the effector domains of chicken IgA or 
IgY, may, in a similar way, be used as a therapeutic agent 
against Campylobacter infection. The work described in 
this study, forms the basis for the development of such 
chimeric antibodies. The advantages of seeds include 
inexpensive production by standard agricultural prac-
tices, excellent stability of the antibodies in the seeds 
and the possible protection of the nanobodies against 
degradation in the gastrointestinal tract of the chickens 
[64]. Riazi et al. [65] reported that pentamers of flagella-
specific nanobodies interfere with the motility of C. jejuni 
and lead to the reduction of colonization by C. jejuni in 
the caecum of treated chickens.
In conclusion, we isolated nanobodies against the 
essential virulence factor MOMP. Since these recog-
nize conserved epitopes, present on C. jejuni and C. coli 
strains, they could potentially be used in therapy and as a 
diagnostic tool [49, 65–67].
Figure 7 Nanobody-coated beads agglutinate C. jejuni KC40 cells. The His‑tagged nanobodies were coupled to magnetic dynabeads, lead‑
ing to multimerization. A Nb84 coupled to dynabeads causes agglutination of KC40 cells. B As a negative control, dynabeads coated with anti‑E. 
coli nanobodies were mixed with KC40 cells. No agglutination was observed in this case. C The C. jejuni KC40 bacteria and D the beads coated with 
Nb84. The results were observed by phase contrast microscopy, using a ×100 oil immersion objective.
Additional files
Additional file 1. Results of the ELISA performed to measure the 
binding of anti-Campylobacter nanobodies to different Campylo-
bacter isolates. Whole‑cell ELISA was used to identify the anti‑Campylo-
bacter nanobodies with a broad specificity. C. jejuni isolates from poultry 
or faeces of human patients, as well as C. coli strains were tested.
Additional file 2. LC–MS/MS identifies the MOMP as a target for the 
nanobodies. Proteins recognized by the anti‑Campylobacter nanobodies 
were isolated by a pull‑down. After digestion of the proteins with trypsin, 
the peptides were analysed via LC‑MS. The five peptides corresponding 
with the MOMP of C. jejuni NCTC 11168 (UniProtKB ‑ P80672) are specified 
by the black boxes.
Additional file 3. ELISA to determine the binding of anti-Campy-
lobacter nanobodies to MOMP. Purified MOMP (1 µg/mL) was coated 
and nanobodies were subsequently added at a concentration of 50 µg/
mL. Mouse anti‑Histidine tag monoclonal antibody and goat anti‑mouse 
IgG conjugated to alkaline phosphatase were used for the development 
of the ELISA. The experiment was performed in duplicate and the mean of 
the obtained results is shown. The error bars represent the standard devia‑
tions. As a negative control, an anti‑F4 nanobody was used.
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Abbreviations
BSA: bovine serum albumin; CDR: complementarity‑determining region; His: 
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Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HDG, JPH, FP, FH and AM conceived the study. JE and GGH immunized the 
alpaca and isolated Campylobacter specific nanobodies. CV purified the anti‑
Campylobacter nanobodies and selected those with broad specificity. IDdO 
and CV identified the antigen of the nanobodies and CV further characterised 
the interactions between the nanobodies and the MOMP. DV performed the 
LC‑MS experiments. KM helped with the MST experiments and the analysis of 
the obtained results. CV, HDG and JPH interpreted the results and CV wrote 
the article. All authors read and approved the final manuscript.
Acknowledgements
We thank Dr. Delphine Martiny (Department of Microbiology, Iris‑lab Brussels) 
for providing us with human C. jejuni strains and Dr. Marc Heyndrickx (the 
Institute for Agricultural and Fisheries Research, Technology and Food Science 
Unit—Food safety, ILVO) for providing C. jejuni and C. coli strains.
Funding
The research that yielded these results, was funded by the Belgian Federal 
Public Service of Health, Food Chain Safety and Environment through the 
Contract RF 13/6272 CampyNanoCure. KM is funded by an FWO postdoctoral 
fellowship.
Author details
1 Structural Molecular Microbiology, VIB, Pleinlaan 2, 1050 Brussels, Belgium. 
2 Structural Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050 Brus‑
sels, Belgium. 3 Genetische Virologie, Vrije Universiteit Brussel, Pleinlaan 2, 
1050 Brussels, Belgium. 4 Department of Pathology, Bacteriology and Avian 
Diseases, Faculty of Veterinary Medicine, Ghent University, Salisburylaan 133, 
9820 Merelbeke, Belgium. 5 VIB Nanobody Service Facility, Vrije Universiteit 
Brussel, Pleinlaan 2, 1050 Brussels, Belgium. 6 Faculty of Medicine and de Duve 
Institute, Université Catholique de Louvain, Avenue Hippocrate 74, 1200 Brus‑
sels, Belgium. 
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 25 July 2017   Accepted: 19 November 2017
References
 1. Ruiz‑Palacios GM (2007) The health burden of Campylobacter infection 
and the impact of antimicrobial resistance: playing chicken. Clin Infect 
Dis 44:701–703
 2. Pires SM, Fischer‑Walker CL, Lanata CF, Devleesschauwer B, Hall AJ, Kirk 
MD, Duarte ASR, Black RE, Angulo FJ (2015) Aetiology‑specific estimates 
of the global and regional incidence and mortality of diarrhoeal diseases 
commonly transmitted through food. PLoS One 10:e0142927
 3. Waage AS, Vardund T, Lund V, Kapperud G (1999) Detection of small num‑
bers of Campylobacter jejuni and Campylobacter coli cells in environmen‑
tal water, sewage, and food samples by a seminested PCR assay. Appl 
Environ Microbiol 65:1636–1643
 4. Coker AO, Isokpehi RD, Thomas BN, Amisu KO, Larry OC (2002) Human 
campylobacteriosis in developing countries. Emerg Infect Dis 8:237–244
 5. Moore JE, Corcoran D, Dooley JSG, Fanning S, Lucey B, Matsuda M, 
McDowell DA, Mégraud F, Millar BC, O’Mahony R, O’Riordan L, O’Rourke 
M, Rao JR, Rooney PJ, Sails A, Whyte P (2005) Campylobacter. Vet Res 
36:351–382
 6. Young KT, Davis LM, Dirita VJ (2007) Campylobacter jejuni: molecular biol‑
ogy and pathogenesis. Nat Rev Microbiol 5:665–679
 7. Hahn AF (1998) Guillain–Barré syndrome. Lancet 352:635–641
 8. Nachamkin I, Allos BM, Ho T (1998) Campylobacter species and Guillain–
Barré syndrome. Clin Microbiol Rev 11:555–567
 9. Horrocks SM, Anderson RC, Nisbet DJ, Ricke SC (2009) Incidence and 
ecology of Campylobacter jejuni and coli in animals. Anaerobe 15:18–25
 10. Corry JE, Atabay HI (2001) Poultry as a source of Campylobacter and 
related organisms. Symp Ser Soc Appl Microbiol 90:96S–114S
 11. Thibodeau A, Fravalo P, Yergeau É, Arsenault J, Lahaye L, Letellier A (2015) 
Chicken caecal microbiome modifications induced by Campylobacter 
jejuni colonization and by a non‑antibiotic feed additive. PLoS One 
10:e0131978
 12. Beery JT, Hugdahl MB, Doyle MP (1988) Colonization of gastrointes‑
tinal tracts of chicks by Campylobacter jejuni. Appl Environ Microbiol 
54:2365–2370
 13. EFSA (2010) Scientific report of EFSA: analysis of the baseline survey on 
the prevalence of Campylobacter in broiler batches and of Campylobacter 
and Salmonella on broiler carcasses in the EU, 2008. EFSA J 8:1503
 14. Herman L, Heyndrickx M, Grijspeerdt K, Vandekerchove D, Rollier I, De 
Zutter L (2003) Routes for Campylobacter contamination of poultry meat : 
Additional file 4. Binding curve of Nb22 with purified MOMP 
obtained in a saturation binding experiment using MST analysis. 
The formation of Nb22‑MOMP complexes was measured at constant 
concentrations of the fluorescently labelled Nb22 (32 nM) and varying 
concentrations of unlabelled MOMP (0.3 nM to 5 µM). Data were normal‑
ized to ΔFnorm [‰]. The error bars represent the standard deviations.
Additional file 5. ELISA to assess the interaction between Campy-
lobacter-specific nanobodies and purified MOMP. The saturation 
binding curve of the interaction between coated MOMP (1 µg/mL) and 
a His‑tagged nanobody (1 × 10−6 to 1 × 102 µg/mL) was obtained via 
ELISA. The dose‑dependent inhibitory effect of a strep‑tagged nanobody 
(1 × 10−6 to 1 × 102 µg/mL) on the interaction between His‑tagged Nb84 
(5.10−2 µg/mL) and MOMP (1 µg/mL), is demonstrated in the competition 
binding curve. Inhibition by strep‑tagged (A) Nb5, (B) Nb22, (C) Nb23, 
(D) Nb24, (E) Nb49, (F) 84, (G) Nb15, (H) Nb32, (I) Nb34, (J) Nb45, (K) Nb48 
and (L) Nb63, was assessed. The ELISA was developed with mouse anti‑
Histidine tag monoclonal antibody and goat anti‑mouse IgG conjugated 
to alkaline phosphatase. The error bars represent the standard deviations.
Additional file 6. Alignment of amino acid sequences of the 
MOMP-encoding porA-gene. The porA gene of the C. jejuni and C. coli 
isolates (Table 1) was amplified using PCR and aligned, using C. jejuni 
KC40 as a reference strain, to identify conserved regions. The PCR was 
performed with the primers F3 (5′‑ATGAAACTAGTTAAACTTAGTTTA‑3′) 
and R3 (5′‑GAATTTGTAAAGAGCTTGAAG‑3′). External loops are labelled 
from L1 to L7 and β‑strands are underlined, based on the MOMP structure 
determined by Ferrara et al. [39]. Loops L3 and L6 are the most conserved 
in sequence and number of amino acids.
Additional file 7. Sequence conservation of porA gene mapped on 
MOMP crystal structure. The sequence conservation in the alignment 
of the porA gene of 28 Campylobacter isolates (Table 1), is visualised on 
the surface of MOMP. Blue corresponds to high amino acid sequence con‑
servation and white with low conservation. High variability is observed in 
the extracellular loops, while the sequence encoding the transmembrane 
β‑barrel is highly conserved. (Left) side view and (right) top view.
Additional file 8. Sequence variability in L3 and L6 of the MOMP 
encoding sequences from C. jejuni and C. coli strains. For the analysis 
of L3, sequences were obtained from the NCBI database using Blastp with 
the MOMP encoding sequence of C. jejuni KC40 as a query. The analysis of 
L6, was based on porA sequences in the MLSTdb database.
Page 13 of 14Vanmarsenille et al. Vet Res  (2017) 48:86 
epidemiological study from hatchery to slaughterhouse. Epidemiol Infect 
131:1169–1180
 15. Hermans D, Pasmans F, Messens W, Martel A, Van Immerseel F, Rasschaert 
G, Heyndrickx M, Van Deun K, Haesebrouck F (2012) Poultry as a host for 
the zoonotic pathogen Campylobacter jejuni. Vector Borne Zoonotic Dis 
12:89–98
 16. Messens W, Hartnett E, Gellynck X, Viaene J, Halet D, Herman L, Gri‑
jspeerdt K (2007) Quantitative risk assessment of human campylobac‑
teriosis through the consumption of chicken meat in Belgium. In: XVIII 
European symposium on the quality of poultry meat and XII European 
symposium on the quality of eggs and egg products. 167–168
 17. Newell DG, Elvers KT, Dopfer D, Hansson I, Jones P, James S, Gittins J, 
Stern NJ, Davies R, Connerton I, Pearson D, Salvat G, Allen VM (2011) 
Biosecurity‑based interventions and strategies to reduce Campylobacter 
spp. on poultry farms. Appl Environ Microbiol 77:8605–8614
 18. Lin J (2009) Novel approaches for Campylobacter control in poultry. 
Foodborne Pathog Dis 6:755–765
 19. Wagenaar JA, Mevius DJ, Havelaar AH (2006) Campylobacter in primary 
animal production and control strategies to reduce the burden of human 
campylobacteriosis. Rev Sci Tech 25:581–594
 20. Moore JE, Barton MD, Blair IS, Corcoran D, Dooley JSG, Fanning S, Kempf 
I, Lastovica AJ, Lowery CJ, Matsuda M, McDowell DA, McMahon A, 
Millar BC, Rao JR, Rooney PJ, Seal BS, Snelling WJ, Tolba O (2006) The 
epidemiology of antibiotic resistance in Campylobacter. Microbes Infect 
8:1955–1966
 21. Phillips I, Casewell M, Cox T, De Groot B, Friis C, Jones R, Nightingale C, 
Preston R, Waddell J (2004) Does the use of antibiotics in food animals 
pose a risk to human health? A critical review of published data. J Antimi‑
crob Chemother 53:28–52
 22. Bratz K, Gölz G, Janczyk P, Nöckler K, Alter T (2015) Analysis of in vitro 
and in vivo effects of probiotics against Campylobacter spp. Berl Munch 
Tierarztl Wochenschr 128:155–162
 23. Hermans D, Martel A, Van Deun K, Verlinden M, Van Immerseel F, Garmyn 
A, Messens W, Heyndrickx M, Haesebrouck F, Pasmans F (2010) Intestinal 
mucus protects Campylobacter jejuni in the ceca of colonized broiler 
chickens against the bactericidal effects of medium‑chain fatty acids. 
Poult Sci 89:1144–1155
 24. Hermans D, Van Deun K, Messens W, Martel A, Van Immerseel F, Haese‑
brouck F, Rasschaert G, Heyndrickx M, Pasmans F (2011) Campylobacter 
control in poultry by current intervention measures ineffective: urgent 
need for intensified fundamental research. Vet Microbiol 152:219–228
 25. Wagenaar JA, Van Bergen MAP, Mueller MA, Wassenaar TM, Carlton RM 
(2005) Phage therapy reduces Campylobacter jejuni colonization in broil‑
ers. Vet Microbiol 109:275–283
 26. Line JE, Svetoch EA, Eruslanov BV, Perelygin VV, Mitsevich EV, Mitsevich 
IP, Levchuk VP, Svetoch OE, Seal BS, Siragusa GR, Stern NJ (2008) Isolation 
and purification of enterocin E‑760 with broad antimicrobial activity 
against gram‑positive and gram‑negative bacteria. Antimicrob Agents 
Chemother 52:1094–1100
 27. Sahin O, Zhang Q, Meitzler JC, Harr BS, Morishita TY, Mohan R (2001) 
Prevalence, antigenic specificity, and bactericidal activity of poultry 
anti‑Campylobacter maternal antibodies. Appl Environ Microbiol 
67:3951–3957
 28. Sahin O, Luo N, Huang S, Zhang Q (2003) Effect of Campylobacter‑specific 
maternal antibodies on Campylobacter jejuni colonization in young chick‑
ens. Appl Environ Microbiol 69:5372–5379
 29. Tsubokura K, Berndtson E, Bogstedt A, Kaijser B, Kim M, Ozeki M (1997) 
Oral administration of antibodies as prophylaxis and therapy in Campylo-
bacter jejuni‑infected chickens. Clin Exp Immunol 108:451–455
 30. Hermans D, Van Steendam K, Verbrugghe E, Verlinden M, Martel A, 
Seliwiorstow T, Heyndrickx M, De Zutter L, Deforce D, Pasmans F (2014) 
Passive immunization to reduce Campylobacter jejuni colonization and 
transmission in broiler chickens. Vet Res 45:27
 31. Hamers‑Casterman C, Atarhouch T, Muyldermans S, Robinson G, Hamers 
C, Bajyana S, Bendahman N, Hamers R (1993) Naturally occurring antibod‑
ies devoid of light chains. Nature 363:446–448
 32. Harmsen MM, De Haard HJ (2007) Properties, production, and applica‑
tions of camelid single‑domain antibody fragments. Appl Microbiol 
Biotechnol 77:13–22
 33. Muyldermans S, Baral TN, Retamozzo VC, De Baetselier P, De Genst E, 
Kinne J, Leonhardt H, Magez S, Nguyen VK, Revets H, Rothbauer U, 
Stijlemans B, Tillib S, Wernery U, Wyns L, Hassanzadeh‑Ghassabeh G, 
Saerens D (2009) Camelid immunoglobulins and nanobody technology. 
Vet Immunol Immunopathol 128:178–183
 34. Rubinchik S, Seddon A, Karlyshev AV (2012) Molecular mechanisms and 
biological role of Campylobacter jejuni attachment to host cells. Eur J 
Microbiol Immunol (Bp) 2:32–40
 35. Al‑Adwani SR, Crespo R, Shah DH (2013) Production and evaluation 
of chicken egg‑yolk‑derived antibodies against Campylobacter jejuni 
colonization‑associated proteins. Foodborne Pathog Dis 10:624–631
 36. Mahdavi J, Pirinccioglu N, Oldfield NJ, Carlsohn E, Stoof J, Aslam A, Self T, 
Cawthraw SA, Petrovska L, Colborne N, Sihlbom C, Borén T, Wooldridge 
KG, Ala’Aldeen DAA (2014) A novel O‑linked glycan modulates Campy-
lobacter jejuni major outer membrane protein‑mediated adhesion to 
human histo‑blood group antigens and chicken colonization. Open Biol 
4:130202
 37. Wu Z, Periaswamy B, Sahin O, Yaeger M, Plummer P, Zhai W, Shen Z, Dai L, 
Chen SL, Zhang Q (2016) Point mutations in the major outer membrane 
protein drive hypervirulence of a rapidly expanding clone of Campylo-
bacter jejuni. Proc Natl Acad Sci U S A 113:10690–10695
 38. Dé E, Jullien M, Labesse G, Pagès JM, Molle G, Bolla JM (2000) MOMP 
(major outer membrane protein) of Campylobacter jejuni; a versatile pore‑
forming protein. FEBS Lett 469:93–97
 39. Ferrara LGM, Wallat GD, Moynié L, Dhanasekar NN, Aliouane S, Acosta‑
Gutiérrez S, Pagès JM, Bolla JM, Winterhalter M, Ceccarelli M, Naismith 
JH (2016) MOMP from Campylobacter jejuni is a trimer of 18‑stranded 
β‑barrel monomers with a  Ca2+ ion bound at the constriction zone. J Mol 
Biol 428:4528–4543
 40. Pardon E, Laeremans T, Triest S, Rasmussen SGF, Wohlköning A, Ruf A, 
Muyldermans S, Hol WGJ, Kobilka BK, Steyaert J (2014) A general protocol 
for the generation of nanobodies for structural biology. Nat Protoc 
9:674–693
 41. Arbabi Ghahroudi M, Desmyter A, Wyns L, Hamers R, Muyldermans S 
(1997) Selection and identification of single domain antibody fragments 
from camel heavy‑chain antibodies. FEBS Lett 414:521–526
 42. Conrath KE, Lauwereys M, Galleni M, Matagne A, Frère JM, Kinne J, Wyns 
L, Muyldermans S (2001) β‑Lactamase inhibitors derived from single‑
domain antibody fragments elicited in the Camelidae. Antimicrob Agents 
Chemother 45:2807–2812
 43. Dagert M, Ehrlich SD (1979) Prolonged incubation in calcium chloride 
improves the competence of Escherichia coli cells. Gene 6:23–38
 44. Hobb RI, Fields JA, Burns CM, Thompson SA (2009) Evaluation of proce‑
dures for outer membrane isolation from Campylobacter jejuni. Microbiol‑
ogy 155:979–988
 45. Arts IS, Vertommen D, Baldin F, Laloux G, Collet JF (2016) Comprehen‑
sively characterizing the thioredoxin interactome in vivo highlights the 
central role played by this ubiquitous oxidoreductase in redox control. 
Mol Cell Proteom 15:2125–2140
 46. Shang X, Marchioni F, Sipes N, Evelyn CR, Jerabek‑Willemsen M, Duhr S, 
Seibel W, Wortman M, Zheng Y (2012) Rational design of small molecule 
inhibitors targeting RhoA subfamily Rho GTPases. Chem Biol 19:699–710
 47. Zhang Q, Meitzler JC, Huang S, Morishita T (2000) Sequence polymor‑
phism, predicted secondary structures, and surface‑exposed conforma‑
tional epitopes of Campylobacter major outer membrane protein. Infect 
Immun 68:5679–5689
 48. Moonens K, Van Den Broeck I, Okello E, Pardon E, De Kerpel M, Remaut 
H, De Greve H (2015) Structural insight in the inhibition of adherence of 
F4 fimbriae producing enterotoxigenic Escherichia coli by llama single 
domain antibodies. Vet Res 46:14
 49. Virdi V, Coddens A, De Buck S, Millet S, Goddeeris BM, Cox E, De Greve 
H, Depicker A (2013) Orally fed seeds producing designer IgAs protect 
weaned piglets against enterotoxigenic Escherichia coli infection. Proc 
Natl Acad Sci U S A 110:11809–11814
 50. Rivoal K, Ragimbeau C, Salvat G, Collin P, Ermel G (2005) Genomic diver‑
sity of Campylobacter coli and Campylobacter jejuni isolates recovered 
from free‑range broiler farms and comparison with isolates of various 
origins. Appl Environ Microbiol 71:6216–6227
 51. Najdenski H, Heyndrickx M, Herman L, Messens W (2008) Fla‑DGGE 
analysis of Campylobacter jejuni and Campylobacter coli in cecal samples 
of broilers without cultivation. Vet Microbiol 127:196–202
Page 14 of 14Vanmarsenille et al. Vet Res  (2017) 48:86 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 52. Cody AJ, Maiden MJC, Dingle KE (2009) Genetic diversity and stability of 
the porA allele as a genetic marker in human Campylobacter infection. 
Microbiology 155:4145–4154
 53. Campylobacter Multilocus Sequence Typing website. https://pubmlst.
org/campylobacter/. Accessed 23 Oct 2017
 54. National Center for Biotechnology Information. https://blast.ncbi.nlm.nih.
gov/Blast.cgi?PAGE=Proteins. Accessed 23 Oct 2017
 55. Höök H, Fattah MA, Ericsson H, Vågsholm I, Danielsson‑Tham ML (2005) 
Genotype dynamics of Campylobacter jejuni in a broiler flock. Vet Micro‑
biol 106:109–117
 56. Kudirkiene E, Malakauskas M, Malakauskas A, Bojesen AM, Olsen JE (2010) 
Demonstration of persistent strains of Campylobacter jejuni within broiler 
farms over a 1‑year period in Lithuania. J Appl Microbiol 108:868–877
 57. Huang S, Sahin O, Zhang Q (2007) Infection‑induced antibodies against 
the major outer membrane protein of Campylobacter jejuni mainly recog‑
nize conformational epitopes. FEMS Microbiol Lett 272:137–143
 58. Islam A, Raghupathy R, Albert MJ (2010) Recombinant PorA, the major 
outer membrane protein of Campylobacter jejuni, provides heterologous 
protection in an adult mouse intestinal colonization model. Clin Vaccine 
Immunol 17:1666–1671
 59. Saerens D, Ghassabeh GH, Muyldermans S (2008) Single‑domain antibod‑
ies as building blocks for novel therapeutics. Curr Opin Pharmacol 
8:600–608
 60. Hultberg A, Tremblay DM, de Haard H, Verrips T, Moineau S, Ham‑
marström L, Marcotte H (2007) Lactobacilli expressing llama VHH frag‑
ments neutralise Lactococcus phages. BMC Biotechnol 7:58
 61. Moor K, Diard M, Sellin ME, Felmy B, Wotzka SY, Toska A, Bakkeren E, 
Arnoldini M, Bansept F, Dal Co A, Völler T, Minola A, Fernandez‑Rodriguez 
B, Agatic G, Barbieri S, Piccoli L, Casiraghi C, Corti D, Lanzavecchia A, 
Regoes RR, Loverdo C, Stocker R, Brumley DR, Hardt WD, Slack E (2017) 
High‑avidity IgA protects the intestine by enchaining growing bacteria. 
Nature 544:498–502
 62. Roche AM, Richard AL, Rahkola JT, Janoff EN, Weiser JN (2015) Antibody 
blocks acquisition of bacterial colonization through agglutination. 
Mucosal Immunol 8:176–185
 63. Shoaf‑Sweeney KD, Larson CL, Tang X, Konkel ME (2008) Identification 
of Campylobacter jejuni proteins recognized by maternal antibodies of 
chickens. Appl Environ Microbiol 74:6867–6875
 64. Zimmermann J, Saalbach I, Jahn D, Giersberg M, Haehnel S, Wedel J, 
Macek J, Zoufal K, Glünder G, Falkenburg D, Kipriyanov SM (2009) Anti‑
body expressing pea seeds as fodder for prevention of gastrointestinal 
parasitic infections in chickens. BMC Biotechnol 9:79
 65. Riazi A, Strong PCR, Coleman R, Chen W, Hirama T, van Faassen H, Henry 
M, Logan SM, Szymanski CM, MacKenzie R, Ghahoudi MA (2013) Pentava‑
lent single‑domain antibodies reduce Campylobacter jejuni motility and 
colonization in chickens. PLoS One 8:e83928
 66. De Meyer T, Muyldermans S, Depicker A (2014) Nanobody‑based prod‑
ucts as research and diagnostic tools. Trends Biotechnol 32:263–270
 67. Deckers N, Saerens D, Kanobana K, Conrath K, Wernery U, Vercruysse J, 
Muyldermans S, Dorny P (2009) Nanobodies, a promising tool for species‑
specific diagnosis of Taenia solium cysticercosis. Int J Parasitol 39:625–633
 68. Sambrook J, Fritsch EF, Maniatis T (1989) Molecular cloning: a laboratory 
manual. Cold Spring Harbor Laboratory Press, New York
 69. Meselson M, Yuan R (1968) DNA restriction enzyme from E. coli. Nature 
217:1110–1114
 70. Zell R, Fritz HJ (1987) DNA mismatch‑repair in Escherichia coli counteract‑
ing the hydrolytic deamination of 5‑methyl‑cytosine residues. EMBO J 
6:1809–1815
